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Introduction
Epstein-Barr virus (EBV), first isolated by Epstein et al. [1] from African Burkitt's lymphoma cell lines, is a ubiquitous herpesvirus with the special characteristic of being an apparent oncogenic agent [2] . Many studies have shed light on the involvement of EBV in the pathogenesis of several kinds of lymphoma, including diffuse large B-cell lymphoma (DLBCL) [2] [3] [4] [5] .
There is long-standing recognition of the correlation between DLBCL and EBV, with EBV-positive DLBCL of the elderly having been included as a new provisional entity in the 2008 WHO lymphoma classification [6] . However, the literature shows that epidemiological features correlate with geographical differences, with there being a higher prevalence of EBV-positive DLBCL among East Asians (4.5-11.4%) than in Western populations (1 -3%) [7] [8] [9] [10] . Furthermore, EBV-positive DLBCL, including EBV-positive DLBCL of the elderly, responds more poorly to treatment and results in worse overall survival (OS) than EBV-negative DLBCL [8] . EBV-encoded mRNA (EBER) in situ hybridization (ISH) is the most common method used for detecting EBV status in DLBCL. However, no uniform criteria for the percentage of EBVpositive cells in EBV-positive DLBCL have been agreed upon until now, resulting in difficulties in evaluating the true incidence of disease prevalence [8, 11, 12] . It is worth noting that, other than EBER, the quantification of EBV DNA in peripheral blood has been demonstrated to be useful for the diagnosis and monitoring of EBV-associated lymphomas [13] [14] [15] [16] . Furthermore, EBV DNA in peripheral blood detected by PCR could be derived from two different samples, as follows: a liquid component of plasma or serum, and a cell component of mononuclear cells or whole blood. A prospective study reported by Suzuki et al. [16] showed the prognostic and monitoring value of mononuclear cell EBV DNA to be similar to that of plasma EBV DNA in extranodal natural killer cell/T-cell lymphoma (NKTCL), nasal type, and it is generally accepted that plasma EBV DNA is a better tumour marker than EBER ISH in NKTCL and Hodgkin's lymphoma (HL). However, not only is there no literature on the clinicopathological features and prognostic value of EBV DNA in DLBCL in comparison with EBV DNA in whole blood and the conventional method of EBER ISH, but there are also no reports on the significance of EBV DNA in EBV-negative patients according to the 2008 WHO classification of lymphoma [6] ; investigation of this was the first objective of our study.
Detection of EBV DNA by the use of whole blood specimens has the advantage of convenience in terms of sample handing and procurement, and monitoring of the dynamic changes in EBV DNA loads, in comparison with EBER ISH. To address this issue further, we also assessed the value of the dynamic changes in EBV DNA in whole blood for DLBCL patients as a biomarker for therapeutic response and prognostication after standard treatments.
Materials and methods

Patients
Three hundred and twenty-nine DLBCL patients who were newly diagnosed between April 2005 and January 2013 were retrospectively enrolled in our study. Baseline clinical characteristics, including age, gender, Ann Arbor stage (I-IV), the number of sites of extranodal involvement, lactate dehydrogenase, ECOG performance status, and B symptoms, were all available. The International Prognostic Index was used for risk stratification. The Hans classification of germinal centre B-cell (GCB) or non-GCB type was used for the patients. The firstline treatments of all of the de novo DLBCL cases are shown in Table S1 .
EBV DNA analysis by real-time PCR The peripheral whole blood sample was collected in an EDTAcontaining tube for each patient. DNA from whole blood was extracted with the EBV PCR Fluorescence Quantitative Diagnostic Kit (Da An Gene Co., Sun Yat-sen University, China). Quantification of EBV-specific sequences was performed by real-time quantitative PCR with ABI PRISM 7500 (Applied Biosystems, Foster City, CA, USA). The copy number of EBV DNA in each sample was calculated from a standard curve with a cut-off value of 5 × 10 3 copies/mL.
EBER ISH
The presence of EBV was investigated with EBER ISH (EBER PNA Probe, ISH-5022; ZSGB-BIO, Beijing, China). The study was carried out on 3-μm-thick sections from paraffinembedded biopsy specimens. The paraffin-embedded tissue sections were dewaxed in xylene, treated with proteinase K, and hybridized with digoxigenin-labelled probe, with a cut-off value of 50% EBV-positive cells for EBER positivity [8] .
Statistical analysis
All statistical analyses were performed with SPSS for Windows (version 17.0; IBM Corporation, Armonk, NY, USA). OS was defined as the time from diagnosis to death owing to any cause by the end of follow-up. OS was evaluated with the Kaplan-Meier method. A p-value of <0.05 was considered to be significant.
Results
Patients' clinical characteristics in relation to EBV DNA and EBER Three hundred and twenty-nine patients were retrospectively enrolled in our study, with tumour tissue specimens of 232 (70.5%) patients being available for EBER ISH, and only 189 (57.4%) patients having pretreatment whole blood specimens for EBV DNA analysis. EBER positivity was found in 24 (10.3%) of the 232 patients, and EBV DNA positivity was found in 18 (9.5%) of the 189 patients. There were 138 (138/329, 41.9%) patients for whom EBER status was available and whose EBV DNA in whole blood was detected at presentation. Among all the 138 patients, there were 128 (92.8%) patients whose EBER ISH status and EBV DNA status were concordant; ten (7.8%) patients were positive for both, and 118 (92.2%) patients were negative for both. Discordant results were found in ten (7.2%) patients; these are all shown in Table S2 . The baseline characteristics according to EBV status assessed by EBER ISH and EBV DNA are described in Table 1 . There was a statistically significant male dominance, based on both pretreatment EBV DNA and EBER (p 0.01 and p 0.03, respectively). Twelve (92.3%) of 13 EBV DNA-positive patients were classified as non-GCB type (p 0.03), and 13 (76.5%) of 17 of EBER-positive patients were classified as non-GCB type, with a trend for statistical significance (p 0.08).
Comparison of the prognostic values of pretreatment EBV DNA and EBER
The follow-up results of the statuses of all 329 patients enrolled in this study were obtained on the end date of September 2014, with a median follow-up of 38 months (range, 19-114 months). Ninety-nine patients (30.1%) died, and the 3-year estimated OS was 68.0% ± 2.8% among all patients.
Not only did OS estimation differ between the EBER-positive and EBER-negative groups, but also worse OS was observed in the pretreatment EBV DNA-positive group than in the EBV DNA-negative group (p 0.03 and p < 0.01, respectively); this is shown in Fig. 1 . In the 138 patients who were available for both analyses, a significant p-value of <0.01 was also observed between the EBV-positive (defined as EBV DNA-positive or EBER-positive) group and the EBV-negative (defined as EBV DNA-negative and EBER-negative) group.
Three different multivariate models (model 1, model 2, and model 3) were used to investigate the independent prognostic value of EBV DNA, EBER, and EBV, respectively. The three models included the same variables (treatment arm without rituximab, sex, and International Prognostic Index score and its components), except for EBV DNA for model 1, EBER for model 2, and EBV for model 3. Multivariate analysis showed that both EBV DNA (hazard ratio 3.71, 95% CI 1.78-7.74, p < 0.01) and EBER (hazard ratio 2.03, 95% CI 1.03-4.00, p 0.04) were independent prognostic factors for OS. Furthermore, EBV positivity (hazard ratio 3.31, 95% CI 1.52-7.21, p < 0.01) retained its significance for worse OS in model 3. All of these results are shown in Table 2 . Evaluation of the prognostic value of the dynamic quantitative changes in EBV DNA with therapy For the 18 patients with elevated levels of pretreatment EBV DNA, we evaluated EBV DNA as a tumour marker after each cycle of treatment in the standard treatment of six cycles. Detailed information on the 18 patients is shown in Table 3 . The median age of the 18 patients was 57 years (range, 31-75 years). The dynamic continuous quantitative changes of all 18 pretreatment EBV DNA-positive patients, which were classified as complete response (CR)/CR undefined, partial response, and no response (NR), are shown in Fig. 2 . The median pretreatment EBV DNA copy numbers of all 18 patients were 3.70 × 10 6 /mL (range, 6.23 × 10 3 /mL to 4.72 × 10 7 /mL). Specifically, we can see that, in patients in the CR/CR-undefined group, the viral load had dropped to undetectable levels immediately after the therapy of the first cycle, and had never risen to detectable levels. Similarly, in the partial response group, the EBV DNA loads of the patients were almost at an undetectable level after the third or fourth cycle. In contrast, patients in the NR group all still had elevated levels of EBV DNA after the third cycle, and some even had elevated levels after the sixth cycle of standard treatment. In order to determine the cycle in which the EBV DNAnegative transformation (from detectable to undetectable levels) could better predict survival outcomes for the patients with pretreatment EBV DNA positivity, the log-rank survival for cycles 1, 2 and 3 was analysed. The results revealed that patients who were EBV DNA-negative had a markedly superior OS to that of patients who were still EBV DNA-positive after the third cycle (EBV DNA-negative/cycle 3) (p < 0.01; Fig. S1 ); the p-value was 0.06 after the first cycle and 0.70 after the second cycle (data not shown). The estimated 2-year OS was 80.2% ± 12.8% for the EBV DNA-negative/cycle 3 group, whereas no patients in the positive group were alive after 2 years. Further investigation also showed that EBV DNAnegative/cycle 3 patients had a similar OS (p 0.66) to patients whose pretreatment EBV DNA was negative.
Discussion
EBV-positive DLBCL of the elderly is characterized by a high age distribution, with an arbitrary cut-off of 50 years (median, 71 years; range, 50-91 years) in the current 2008 WHO classification [6] ; the results from our study showed that the median age of EBER-positive patients was 55 years (range, 22-75 years), and that of EBV DNA-positive patients was 57 years (range, 31-75 years). However, three EBV DNA-positive patients were younger than 50 years (31, 45 and 47 years, respectively), as were four EBER-positive patients (22, 39, 46 and 48 years, respectively); it has been previously reported in the literature that younger patients can be also affected [16] [17] [18] . Furthermore, no statistical significance was observed regarding age distribution (50 years vs. <50 years), as assessed by either EBER or EBV DNA. Further investigations should be focused on the clinical characteristics and survival outcomes of EBV-positive DLBCL patients aged <50 years. The current definition of EBV-positive DLBCL of the elderly [6] may face a challenge if a substantial proportion of EBV-positive DLBCLs are also observed in younger patients in other studies. In contrast to another report from northern China showing that the incidence of EBV positivity in patients with DLBCL aged >50 years was only 3.8% (8/212), by using a cut-off of >50% EBER positivity, the incidence detected either by EBER (10.3%) or by EBV DNA analysis (9.5%) from our centre was consistent with the findings among East Asians (8.7-11.4%) reported in the past [7, 8, 19] . Although 92.8% (128/138) concordance was observed between pretreatment EBV DNA and EBER ISH, the relatively high ratio (7.2%, 10/138) of the inconsistent status needs to be explained. Considering one possible explanation for the discrepancy between EBV DNA positivity and EBER negativity, Kanakry et al. [20] suggested that, in patients with human immunodeficiency virus infection, chronic active EBV, organ transplantation, and primary EBV infection, EBV DNA may reflect the presence of virions rather than genomic viral DNA released from the latently infected cells in HL. This may also apply to patients with DLBCL. Analysis of the other circumstances requires further investigations. With respect to the prognostic value of EBER positivity, Park et al. [21] reported that patients with EBV-positive DLBCL, including EBV-positive DLBCL of the elderly, responded more poorly to treatment, with a worse outcome regarding both OS and progression-free survival, than patients with EBV-negative DLBCL. In addition, significantly worse survival was observed in EBVpositive DLBCL patients if CD30 expression was also observed [22] . However, a negative impact of EBV infection on DLBCL survival was not observed in North American patients [20] .
In this study, pretreatment EBV DNA in whole blood and EBER showed 92.8% concordance, which was similar to the 96% concordance between plasma EBV DNA and EBER in HL reported by Kanakry [20] . Significantly inferior OS was observed in patients with positive EBV status assessed by EBV DNA than in patients with positive EBV status detected by EBER (p < 0.01 vs. p 0.03, respectively). Although both EBV DNA and EBER were independent predictors of worse OS, we still found that the hazard ratio for EBER was inferior to that for EBV DNA, indicating that EBV DNA at diagnosis may be a better prognostic biomarker for OS than the EBER ISH conventionally used in the past. All of these results indicate that EBV DNA is a good indicator for OS, which is similar to the suggestion of Suzuki regarding extranodal NKTCL, nasal type [16] . It is speculated that the positive EBV status detected either by EBV DNA analysis or by EBER has prognostic significance. Just as we had expected, statistical significance was also observed between the EBV-positive and EBV-negative groups, demonstrating that the combination of EBV DNA analysis and EBER might be finally adapted in the clinic in the future.
After analysing each cycle, we found that the EBV DNA status after cycle 3 might be the cut-off for the prognosis of OS rather than the status after the other cycles. We also found that patients who were EBV DNA-negative after cycle 3 had similar results to those of patients whose pretreatment EBV DNA was negative. Therefore, EBV DNA could be used as a monitoring biomarker.
It needs to be emphasized that continuous monitoring is necessary for patients who are EBV DNA-negative after cycle 3, because patients may have worsened survival if the elevated level is detected at any time after cycle 3, as we can observe from patient 9 in the NR group. These patients may be treated in the same way as poor-risk patients, and the superiority of high-dose chemotherapy with stem cell support over conventional methods should be investigated.
To summarize, the retrospective nature of this study, with incomplete data, such as not all patients being available for both analyses (EBER and EBV DNA), is the major limitation. From this study, we can conclude that baseline EBV DNA-positive DLBCL patients have worse OS. Additionally, given the fact that the presence of EBV DNA negativity after cycle 3 of the standard therapy appeared to be vital for these patients in the current study, further larger prospective studies are worth performing, to validate the value of EBV DNA as either a prognostic factor at diagnosis or a monitoring biomarker with therapy and follow-up in DLBCL patients.
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